PPARs link early life nutritional insults to later programmed hypertension and metabolic syndrome

International Journal of Molecular Sciences

Volumn 17, Issue 1, 2016, Pages

  Tain, You Lin ^a   Hsu, Chien Ning ^b,c   Chan, Julie Y H ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Developmental programming; Hypertension; Kidney; Metabolic syndrome; Nutrient sensing; Peroxisome proliferator activated receptor

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; HISTONE ACETYLTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; SIRTUIN 1; SODIUM PROTON EXCHANGE PROTEIN 3; ANTIHYPERTENSIVE AGENT; CARBOHYDRATE DIET; FRUCTOSE; ISOPROTEIN;

DIETARY INTAKE; FRUCTOSE INTAKE; HUMAN; HYPERTENSION; METABOLIC SYNDROME X; NUTRITIONAL ASSESSMENT; NUTRITIONAL INSULT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SALT INTAKE; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CARBOHYDRATE DIET; FEMALE; GENE EXPRESSION REGULATION; GENETICS; KIDNEY; MATERNAL EXPOSURE; METABOLISM; NUTRITIONAL STATUS; PATHOLOGY; PREGNANCY; PRENATAL EXPOSURE; PREVENTION AND CONTROL; SIGNAL TRANSDUCTION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; DIETARY CARBOHYDRATES; FEMALE; FRUCTOSE; GENE EXPRESSION REGULATION; HUMANS; HYPERTENSION; KIDNEY; MATERNAL EXPOSURE; METABOLIC SYNDROME X; NUTRITIONAL STATUS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PROTEIN ISOFORMS; SIGNAL TRANSDUCTION;

EID: 84951783609     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17010020     Document Type: Review

References (62)

1. Ojeda, N.B.; Grigore, D.; Alexander, B.T. Developmental programming of hypertension: Insight from animal models of nutritional manipulation. Hypertension 2008, 52, 44-50. [CrossRef] [PubMed]
2. Tain, Y.L.; Hsu, C.N.; Chan, J.Y.; Huang, L.T. Renal transcriptome analysis of programmed hypertension induced by maternal nutritional insults. Int. J. Mol. Sci. 2015, 16, 17826-17837. [CrossRef] [PubMed]
3. Rinaudo, P.;Wang, E. Fetal programming and metabolic syndrome. Annu. Rev. Physiol. 2012, 74, 107-130. [CrossRef] [PubMed]
4. McMullen, S.; Langley-Evans, S.C.; Gambling, L.; Lang, C.; Swali, A.; McArdle, H.J. A common cause for a common phenotype: The gatekeeper hypothesis in fetal programming. Med. Hypotheses 2012, 78, 88-94. [CrossRef] [PubMed]
5. Efeyan, A.; Comb, W.C.; Sabatini, D.M. Nutrient-sensing mechanisms and pathways. Nature 2015, 517, 302-310. [CrossRef] [PubMed]
6. Azhar, S. Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease. Future Cardiol. 2010, 6, 657-691. [CrossRef] [PubMed]
7. Monsalve, F.A.; Pyarasani, R.D.; Delgado-Lopez, F.; Moore-Carrasco, R. Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases. Mediat. Inflamm. 2013, 2013, 549627. [CrossRef] [PubMed]
8. Ruan, X.; Zheng, F.; Guan, Y. PPARs and the kidney in metabolic syndrome. Am. J. Physiol. Ren. Physiol. 2008, 294, F1032-F1047. [CrossRef] [PubMed]
9. Luo, Z.C.; Xiao, L.; Nuyt, A.M. Mechanisms of developmental programming of the metabolic syndrome and related disorders. World J. Diabetes 2010, 1, 89-98. [CrossRef] [PubMed]
10. Paixão, A.D.; Alexander, B.T. How the kidney is impacted by the perinatal maternal environment to develop hypertension. Biol. Reprod. 2013, 89, 144. [CrossRef] [PubMed]
11. Luyckx, V.A.; Bertram, J.F.; Brenner, B.M.; Fall, C.; Hoy, W.E.; Ozanne, S.E.; Vikse, B.E. Effect of fetal and child health on kidney development and long-term risk of hypertension and kidney disease. Lancet 2013, 382, 273-283. [CrossRef]
12. Tain, Y.L.; Hsieh, C.S.; Lin, I.C.; Chen, C.C.; Sheen, J.M.; Huang, L.T. Effects of maternal L-citrulline supplementation on renal function and blood pressure in offspring exposed to maternal caloric restriction: The impact of nitric oxide pathway. Nitric Oxide 2010, 23, 34-41. [CrossRef] [PubMed]
13. Tain, Y.L.; Lee,W.C.; Hsu, C.N.; Lee,W.C.; Huang, L.T.; Lee, C.T.; Lin, C.Y. Asymmetric dimethylarginine is associated with developmental programming of adult kidney disease and hypertension in offspring of streptozotocin-treated mothers. PLoS ONE 2013, 8, e55420. [CrossRef] [PubMed]
14. Tain, Y.L.; Leu, S.; Wu, K.L.; Lee, W.C.; Chan, J.Y. Melatonin prevents maternal fructose intake-induced programmed hypertension in the offspring: Roles of nitric oxide and arachidonic acid metabolites. J. Pineal Res. 2014, 57, 80-89. [CrossRef] [PubMed]
15. Tain, Y.L.; Lee, W.C.; Leu, S.; Wu, K.L.; Chan, J.Y. High salt exacerbates programmed hypertension in maternal fructose-fed male offspring. Nutr. Metab. Cardiovasc. Dis. 2015, 25, 1146-1151. [CrossRef] [PubMed]
16. Tain, Y.L.; Sheen, J.M.; Yu, H.R.; Chen, C.C.; Tiao, M.M.; Hsu, C.N.; Lin, Y.J.; Kuo, K.C.; Huang, L.T. Maternal melatonin therapy rescues prenatal dexamethasone and postnatal high-fat diet induced programmed hypertension in male rat offspring. Front. Physiol. 2015, 6, 377. [CrossRef]
17. Tain, Y.L.; Sheen, J.M.; Chen, C.C.; Yu, H.R.; Tiao, M.M.; Kuo, H.C.; Huang, L.T. Maternal citrulline supplementation prevents prenatal dexamethasone-induced programmed hypertension. Free Radic. Res. 2014, 48, 580-586. [CrossRef] [PubMed]
18. Tain, Y.L.; Lee, C.T.; Huang, L.T. Long-term effects of maternal citrulline supplementation on renal transcriptome prevention of nitric oxide depletion-related programmed hypertension: The impact of gene-nutrient interactions. Int. J. Mol. Sci. 2014, 15, 23255-23268. [CrossRef] [PubMed]
19. Tain, Y.L.; Chen, C.C.; Sheen, J.M.; Yu, H.R.; Tiao, M.M.; Kuo, H.C.; Huang, L.T. Melatonin attenuates prenatal dexamethasone-induced blood pressure increase in a rat model. J. Am. Soc. Hypertens. 2014, 8, 216-226. [CrossRef] [PubMed]
20. Wu, T.H.; Kuo, H.C.; Lin, I.C.; Chien, S.J.; Huang, L.T.; Tain, Y.L. Melatonin prevents neonatal dexamethasone induced programmed hypertension: Histone deacetylaseinhibition. J. Steroid Biochem. Mol. Biol. 2014, 144, 253-259. [CrossRef] [PubMed]
21. Meher, A.; Sundrani, D.; Joshi, S. Maternal nutrition influences angiogenesis in the placenta through peroxisome proliferator activated receptors: A novel hypothesis. Mol. Reprod. Dev. 2015, 82, 726-734. [CrossRef] [PubMed]
22. Rees, W.D.; McNeil, C.J.; Maloney, C.A. The roles of PPARs in the fetal origins of metabolic health and disease. PPAR Res. 2008, 2008, 459030. [CrossRef] [PubMed]
23. Zana-Taieb, E.; Pham, H.; Franco-Montoya, M.L.; Jacques, S.; Letourneur, F.; Baud, O.; Jarreau, P.H.; Vaiman, D. Impaired alveolarization and intra-uterine growth restriction in rats: A postnatal genome-wide analysis. J. Pathol. 2015, 235, 420-430. [CrossRef] [PubMed]
24. Diep, Q.N.; Amiri, F.; Touyz, R.M.; Cohn, J.S.; Endemann, D.; Neves, M.F.; Schiffrin, E.L. PPARα activator effects on Ang II-induced vascular oxidative stress and inflammation. Hypertension 2002, 40, 866-871. [CrossRef] [PubMed]
25. Usuda, D.; Kanda, T. Peroxisome proliferator-activated receptors for hypertension. World J. Cardiol. 2014, 6, 744-754. [CrossRef] [PubMed]
26. Zarzuelo, M.J.; Jiménez, R.; Galindo, P.; Sánchez, M.; Nieto, A.; Romero, M.; Quintela, A.M.; López-Sepúlveda, R.; Gómez-Guzmán, M.; Bailón, E.; et al. Antihypertensive effects of peroxisome proliferator-activated receptor-β activation in spontaneously hypertensive rats. Hypertension 2011, 58, 733-743. [CrossRef] [PubMed]
27. Hamblin, M.; Chang, L.; Zhang, J.; Chen, Y.E. The role of peroxisome proliferator-activated receptor in blood pressure regulation. Curr. Hypertens. Rep. 2009, 11, 239-245. [CrossRef] [PubMed]
28. Duan, S.Z.; Ivashchenko, C.Y.; Whitesall, S.E.; D'Alecy, L.G.; Duquaine, D.C.; Brosius, F.C., III; Gonzalez, F.J.; Vinson, C.; Pierre, M.A.; Milstone, D.S.; et al. Hypotension, lipodystrophy, and insulin resistance in generalized PPAR-deficient mice rescued from embryonic lethality. J. Clin. Investig. 2007, 117, 812-822. [CrossRef] [PubMed]
29. Todorov, V.T.; Desch, M.; Schmitt-Nilson, N.; Todorova, A.; Kurtz, A. Peroxisome proliferator-activated receptor- is involved in the control of renin gene expression. Hypertension 2007, 50, 939-944. [CrossRef] [PubMed]
30. Choi, S.S.; Park, J.; Choi, J.H. Revisiting PPAR as a target for the treatment of metabolic disorders. BMB Rep. 2014, 47, 599-608. [CrossRef] [PubMed]
31. Michalik, L.; Auwerx, J.; Berger, J.P.; Chatterjee, V.K.; Glass, C.K.; Gonzalez, F.J.; Grimaldi, P.A.; Kadowaki, T.; Lazar, M.A.; O'Rahilly, S.; et al. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol. Rev. 2006, 58, 726-741. [PubMed]
32. Sugden, M.C.; Caton, P.W.; Holness, M.J. PPAR control: It's SIRTainly as easy as PGC. J. Endocrinol. 2010, 204, 93-104. [CrossRef] [PubMed]
33. Blanchard, P.G.; Festuccia, W.T.; Houde, V.P.; St-Pierre, P.; Brûlé, S.; Turcotte, V.; Côté, M.; Bellmann, K.; Marette, A.; Deshaies, Y. Major involvement of mTOR in the PPAR-induced stimulation of adipose tissue lipid uptake and fat accretion. J. Lipid Res. 2012, 53, 1117-1125. [CrossRef] [PubMed]
34. Lemay, D.G.; Hwang, D.H. Genome-wide identification of peroxisome proliferator response elements using integrated computational genomics. J. Lipid Res. 2006, 47, 1583-1587. [CrossRef] [PubMed]
35. Rakhshandehroo, M.; Knoch, B.; Müller, M.; Kersten, S. Peroxisome proliferator-activated receptor α target genes. PPAR Res. 2010, 2010, 612089. [CrossRef] [PubMed]
36. Aleshin, S.; Strokin, M.; Sergeeva, M.; Reiser, G. Peroxisome proliferator-activated receptor (PPAR)β/δ, a possible nexus of PPARα- and PPARβ- dependent molecular pathways in neurodegenerative diseases: Review and novel hypotheses. Neurochem. Int. 2013, 63, 322-330. [CrossRef] [PubMed]
37. Racasan, S.; Braam, B.; Koomans, H.A.; Joles, J.A. Programming blood pressure in adult SHR by shifting perinatal balance of NO and reactive oxygen species toward NO: The inverted Barker phenomenon. Am. J. Physiol. Ren. Physiol. 2005, 288, F626-F636. [CrossRef] [PubMed]
38. Tain, Y.L.; Huang, L.T. Restoration of asymmetric dimethylarginine-nitric oxide balance to prevent the development of hypertension. Int. J. Mol. Sci. 2014, 15, 11773-11782. [CrossRef] [PubMed]
39. Polvani, S.; Tarocchi, M.; Galli, A. PPARg and Oxidative Stress: Con(b) Catenating NRF2 and FOXO. PPAR Res. 2012, 2012, 641087. [CrossRef] [PubMed]
40. Zhang, H.; Shao, Z.; Alibin, C.P.; Acosta, C.; Anderson, H.D. Liganded peroxisome proliferator-activated receptors (PPARs) preserve nuclear histone deacetylase 5 levels in endothelin-treated Sprague-Dawley rat cardiac myocytes. PLoS ONE 2014, 9, e115258. [CrossRef] [PubMed]
41. Saad, S.; Agapiou, D.J.; Chen, X.M.; Stevens, V.; Pollock, C.A. The role of Sgk-1 in the upregulation of transport proteins by PPAR- agonists in human proximal tubule cells. Nephrol. Dial. Transplant. 2009, 24, 1130-1141. [CrossRef] [PubMed]
42. Vallon, V.; Lang, F. New insights into the role of serum- and glucocorticoid-inducible kinase SGK1 in the regulation of renal function and blood pressure. Curr. Opin. Nephrol. Hypertens. 2005, 14, 59-66. [CrossRef] [PubMed]
43. Rizkalla, S.W. Health implications of fructose consumption: A review of recent data. Nutr. Metab. 2010, 7, 82. [CrossRef] [PubMed]
44. Tain, Y.L.;Wu, K.L.; Lee,W.C.; Leu, S.; Chan, J.Y. Maternal fructose-intake-induced renal programming in adult male offspring. J. Nutr. Biochem. 2015, 26, 642-650. [CrossRef] [PubMed]
45. NIH DAVID Bioinformatics Resources 6.7. Available online: http://david.abcc.ncifcrf.gov/ (accessed on 1 December 2015).
46. Koeners, M.P.;Wesseling, S.; Ulu, A.; Sepúlveda, R.L.; Morisseau, C.; Braam, B.; Hammock, B.D.; Joles, J.A. Soluble epoxide hydrolase in the generation and maintenance of high blood pressure in spontaneously hypertensive rats. Am. J. Physiol. Endocrinol. Metab. 2011, 300, E691-E698. [CrossRef] [PubMed]
47. Furuhashi, M.; Saitoh, S.; Shimamoto, K.; Miura, T. Fatty acid-binding protein 4 (FABP4): Pathophysiological insights and potent clinical biomarker of metabolic and cardiovascular diseases. Clin. Med. Insights Cardiol. 2015, 8, 23-33. [CrossRef] [PubMed]
48. Kennedy, D.J.; Chen, Y.; Huang, W.; Viterna, J.; Liu, J.; Westfall, K.; Tian, J.; Bartlett, D.J.; Tang, W.H.; Xie, Z.; Shapiro, J.I.; Silverstein, R.L. CD36 and Na/K-ATPase-α1 form a proinflammatory signaling loop in kidney. Hypertension 2013, 61, 216-224. [CrossRef] [PubMed]
49. Wyrwoll, C.S.; Mark, P.J.; Mori, T.A.; Puddey, I.B.; Waddell, B.J. Prevention of programmed hyperleptinemia and hypertension by postnatal dietary!-3 fatty acids. Endocrinology 2006, 147, 599-606. [CrossRef] [PubMed]
50. Sherman, R.C.; Langley-Evans, S.C. Antihypertensive treatment in early postnatal life modulates prenatal dietary influences upon blood pressure in the rat. Clin. Sci. 2000, 98, 269-275. [CrossRef] [PubMed]
51. Torres, T.S.; D'Oliveira Silva, G.; Aguila, M.B.; de Carvalho, J.J.; Mandarim-De-Lacerda, C.A. Effects of rosiglitazone (a peroxysome proliferator-activated receptor agonist) on the blood pressure and aortic structure in metabolically programmed (perinatal low protein) rats. Hypertens. Res. 2008, 31, 965-975. [CrossRef] [PubMed]
52. Hsu, C.N.; Lee, C.T.; Huang, L.T.; Tain, Y.L. Aliskiren in early postnatal life prevents hypertension and reduces asymmetric dimethylarginine in offspring exposed to maternal caloric restriction. J. Renin Angiotensin Aldosterone Syst. 2015, 16, 506-513. [CrossRef] [PubMed]
53. Gray, C.; Vickers, M.H.; Segovia, S.A.; Zhang, X.D.; Reynolds, C.M. A maternal high fat diet programmes endothelial function and cardiovascular status in adult male offspring independent of body weight, which is reversed by maternal conjugated linoleic acid (CLA) supplementation. PLoS ONE 2015, 10, e0115994. [CrossRef] [PubMed]
54. Yousefipour, Z.; Newaz, M. PPARα ligand clofibrate ameliorates blood pressure and vascular reactivity in spontaneously hypertensive rats. Acta Pharmacol. Sin. 2014, 35, 476-482. [CrossRef] [PubMed]
55. Chung, H.W.; Lim, J.H.; Kim, M.Y.; Shin, S.J.; Chung, S.; Choi, B.S.; Kim, H.W.; Kim, Y.S.; Park, C.W.; Chang, Y.S. High-fat diet-induced renal cell apoptosis and oxidative stress in spontaneously hypertensive rat are ameliorated by fenofibrate through the PPARα-FoxO3a-PGC-1α pathway. Nephrol. Dial. Transplant. 2012, 27, 2213-2225. [CrossRef] [PubMed]
56. Wu, L.; Wang, R.; de Champlain, J.; Wilson, T.W. Beneficial and deleterious effects of rosiglitazone on hypertension development in spontaneously hypertensive rats. Am. J. Hypertens. 2004, 17, 749-756. [CrossRef] [PubMed]
57. Dovinová, I.; Barancik, M.; Majzunova, M.; Zorad, S.; Gajdosechová, L.; Gresová, L.; Cacanyiova, S.; Kristek, F.; Balis, P.; Chan, J.Y. Effects of PPAR agonist pioglitazone on redox-sensitive cellular signaling in young spontaneously hypertensive rats. PPAR Res. 2013, 2013, 541871. [CrossRef] [PubMed]
58. Liang, X.; Xing,W.; He, J.; Fu, F.; Zhang,W.; Su, F.; Liu, F.; Ji, L.; Gao, F.; Su, H.; et al. Magnolol administration in normotensive young spontaneously hypertensive rats postpones the development of hypertension: Role of increased PPAR, reduced TRB3 and resultant alleviative vascular insulin resistance. PLoS ONE 2015, 10, e0120366. [CrossRef] [PubMed]
59. Khan, A.H.; Imig, J.D. Telmisartan provides better renal protection than valsartan in a rat model of metabolic syndrome. Am. J. Hypertens. 2011, 24, 816-821. [CrossRef] [PubMed]
60. Gelosa, P.; Banfi, C.; Gianella, A.; Brioschi, M.; Pignieri, A.; Nobili, E.; Castiglioni, L.; Cimino, M.; Tremoli, E.; Sironi, L. Peroxisome proliferator-activated receptor α agonism prevents renal damage and the oxidative stress and inflammatory processes affecting the brains of stroke-prone rats. J. Pharmacol. Exp. Ther. 2010, 335, 324-331. [CrossRef] [PubMed]
61. Koeners, M.P.;Wesseling, S.; Sánchez, M.; Braam, B.; Joles, J.A. Perinatal Inhibition of NF-kB has long-term antihypertensive and renoprotective effects in fawn-hooded hypertensive rats. Am. J. Hypertens. 2015. [CrossRef]
62. Tenenbaum, A.; Motro, M.; Fisman, E.Z. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: The bezafibrate lessons. Cardiovasc. Diabetol. 2005, 4, 14. [CrossRef] [PubMed]